News
New Study Helps Predict Which Lung Cancer Drugs are Most Likely to Work - 01/10/2012
Researchers at Johns Hopkins have shown that DNA changes in a gene that drives the growth of a form of lung cancer can make the cancer’s cells resistant to cancer drugs. The findings show that some classes of drugs won’t work, and certain types of so-called kinase inhibitors like erlotinib—may be
Roche Warns of Counterfeit Avastin in the U S
The maker of the widely prescribed cancer drug Avastin is warning doctors and patients about counterfeit vials of the product that have been
Counterfeit Drugs | Roche Warns of Counterfeit Cancer Drug in US | Pharmaceutical Manufacturing
The maker of the widely prescribed cancer drug Avastin is warning doctors and patients about counterfeit vials of the product that have been distributed in the U.S.
Infection risk not increased with alemtuzumab : The Lancet Oncology
Infection risk not increased with alemtuzumab. By - Bryant Furlow
Roche Holding's CEO Discusses Q4 2011 Results - Earnings Call Transcript - Seeking Alpha
< p > Roche Holding Ltd. ( < a href='http://seekingalpha.com/symbol/rhhby.pk' title='Roche Hldg Ltd Spons' > RHHBY.PK < /a > ) < /p > < p > Q4 2011 Earnings Call < /p > < p > February 01, 2012 01:00 am ET < /p > < p > < strong > Executives < /strong > < /p > < p > Severin Schwan – Chief Executive
FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications {– Study met
CAMBRIDGE, Mass., January 23, 2012–Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE<sup>®</sup>
Laryngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019 | PRLog
Laryngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019. Laryngeal Cancer Therapeutics Market is Forecast to Show Slow Growth Until 2019 - PR11793534
FDA Notifies Genentech of Violations at Avastin Plant - - BioPharm International
On Sept. 27, 2011, FDA sent Genentech a Form 483 listing several violations at the company?s South San Francisco, California, plant. The violations included problems with investigations into batch failures, inappropriate equipment design, and insufficient protection against contamination. FDA
FDA Removes Avastin Breast Cancer Indication - Pharmaceutical Technology
The breast cancer indication for Avastin has been revoked after FDA Commissioner Margaret A. Hamburg concluded that the drug has not been shown to be safe and effective for this use.
FDA blow for blockbuster Roche drug - FT.com
The US Food and Drug Administration has revoked approval for Roche’s blockbuster drug Avastin to treat breast cancer, dealing a blow to the company and disappointing health groups that have argued the drug has saved lives. Margaret Hamburg, FDA
Refine by Content Type:
Refine by Source:
- www.thelancet.com (859)
- download.thelancet.com (227)
- www.medpagetoday.com (144)
- www.em-consulte.com (136)
- www.biospace.com (99)
- seekingalpha.com (60)
- www.aerzteblatt.de (57)
- www.genengnews.com (48)
- www.webmd.com (25)
- www.prlog.org (22)
- www.pharmaceutical-business-review.com (20)
- www.dddmag.com (20)
